Archive for July 4th, 2014
BDO Unibank Presentation from the Deutsche Bank Depositary Receipts Virtual Investor Conference Now Available for On-demand Viewing
NEW YORK, July 2, 2014 /PRNewswire/ — BDO Unibank, Inc., (Philippine Stock Exchange [PSE]: BDO, ADR Level 1 OTC US: BDOUY), the Philippines’ largest bank in terms of total resources, today announced that their June 26th Deutsche Bank Depositary Receipts Virtual Investor Conference presentation is now available for on-demand viewing.
LINK: www.adr.db.com/dbvic
BDO Unibank, Inc.’s presentation will be available 24/7 for 90 days in “Presentations.” Investors may also download shareholder materials from the virtual trade booth in “Exhibits.”
About BDO Unibank, Inc:
BDO is a full-service universal bank which provides a wide range of corporate and retail banking services. These services include traditional loan and deposit products, as well as treasury, trust banking, investment banking, private banking, cash management, leasing and finance, remittance, insurance, retail cash cards and credit card services.
BDO has one of the largest distribution networks, with 830 operating branches and over 2,300 ATMs nationwide. It also has a branch in Hong Kong as well as 13 overseas remittance and representative offices in Asia, Europe, North America and the Middle East.
BDO ranked as the largest bank in terms of total assets, loans, deposits, capital and trust funds under management based on published statements of condition as of December 31, 2013. For more information, please visit www.bdo.com.ph.
Disclaimer:
This presentation and the presentation materials distributed herewith include forward-looking statements. All statements, other than statements of historical facts that address activities, events, or developments that BDO Unibank, Inc. (“BDO”) expects or anticipates will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. BDO’s actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, including but not limited to price fluctuations, actual demand, exchange rate fluctuations, market shares, competition, changes in legal, financial and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, and other risks and factors beyond our control. In addition, BDO makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.
AMRI Completes Acquisition of Oso Biopharmaceuticals Manufacturing
ALBANY, N.Y., July 2, 2014 /PRNewswire/ — AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI’s strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry.
OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products and their expertise in large-scale commercial production is highly complementary to AMRI’s early stage drug product manufacturing capabilities. Customers will benefit from access to a single source to address their sterile fill/finish needs from Phase 1 development complete to commercial supply.
Total consideration paid was $110 million. AMRI financed the transaction with cash on hand. AMRI anticipates full year run-rate synergies of approximately $3.0 million of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI’s 2014 adjusted diluted EPS. AMRI intends to provide investors with updated 2014 guidance for the combined company when it releases its second quarter 2014 financial results on August 5, 2014.
About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Large Scale Manufacturing (LSM) and Discovery and Development Solutions (DDS). The LSM segment includes Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing, which supports the commercial cGMP manufacturing of complex APIs, starting materials, clinical formulation development and aseptic fill and finish. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
About AMRI Large Scale API and Drug Product Manufacturing
With demonstrated success in Large Scale API and Drug Product Manufacturing, we offer the preeminence and scale to support the chemical development, clinical formulation development, cGMP manufacture and cGMP aseptic formulation and filling of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Our global manufacturing footprint, which also includes manufacturing in Europe and India, provides customers with access to global markets and low-cost manufacturing of APIs or intermediates. In addition, we have the skills and infrastructure to adequately provide complex API research and development, analytical support and support with global regulatory activities. On the Drug Product side, we have expertise with supporting pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. We specialize in vial and pre-filled syringe manufacturing and have lyophilization capabilities for vials. AMRI has the capability to perform small batch manufacturing, but has the capacity to perform filling for larger batches to support Phase III, registration batches and commercial.
About Altaris Capital Partners
Altaris is an investment firm focused exclusively on the healthcare industry. With over $1.3 billion of equity capital under management, Altaris invests in businesses that meet clearly defined healthcare needs. Altaris’ portfolio companies are typically headquartered in North America or Western Europe, but have operations throughout the world. Altaris is based in New York. For more information, please visit www.altariscap.com.
Forward-looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, the potential synergies associated with the OsoBio acquisition and the potential impact on AMRI’s operations and financial results. Readers should not place undue reliance on our forward-looking statements. The company’s actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company’s control. Factors that could cause such differences include, but are not limited to, the ability of the Company to effectively integrate OsoBio’s business; possible negative impacts to the revenue expected to be received by OsoBio following the closing of the transaction; trends in pharmaceutical and biotechnology companies’ outsourcing of chemical research and development, including softness in these markets; sales of Allegra® and the impact of the “at-risk” launch of generic Allegra®, the OTC conversion of Allegra® and the generic and OTC sales of Allegra in Japan on the company’s receipt of significant royalties under the Allegra® license agreement; the success of the sales of other products for which the company receives royalties; the risk that the company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra® license agreements; the risk that clients may terminate or reduce demand under any strategic or multi-year deal; the company’s ability to enforce its intellectual property and technology rights; the company’s ability to obtain financing sufficient to meet its business; the company’s ability to successfully comply with heightened FDA scrutiny on aseptic fill/finish operations; the results of further FDA inspections; the company’s ability to effectively maintain compliance with applicable FDA and DEA regulations; the company’s ability to integrate past or future acquisitions and make such acquisitions accretive to the company’s business model; the company’s ability to take advantage of proprietary technology and expand the scientific tools available to it; the ability of the company’s strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 17, 2014, and the company’s other SEC filings. OsoBio revenue and EBITDA, potential synergies available following closing of the pending transaction and other forward looking information offered by senior management today represent a point-in-time estimate and are based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. EBITDA synergies and 2014 adjusted diluted EPS are only provided on a non-GAAP basis. It is not feasible to provide reconciliation to the most comparable projected U.S. GAAP measure because the excluded items are difficult to predict and estimate and are primarily dependent on future events.
Frost & Sullivan Confers Technology Innovation Leadership Award on TECSYS for its Pioneering Warehouse Management Software
MOUNTAIN VIEW, Calif., July 2, 2014 /PRNewswire/ — Based on its recent analysis of the warehouse management software (WMS) market, Frost & Sullivan recognizes TECSYS with the 2014 North America Frost & Sullivan Award for Technology Innovation Leadership for enabling new levels of productivity, efficiency, cost-savings, and user-friendliness.
TECSYS’s visual logistics technology allows users to perform sophisticated tasks in the supply chain market without any delays, a feat that is not possible with competing WMS technologies that are mainly text based and applicable only for a specific function. The TECSYS WMS is developed on a complete supply chain execution platform that allows the merging of information obtained from various application segments and databases into a single query. It is also the only solution in the market that allows users to adapt and personalize the WMS according to their specific and ever-evolving needs.
“Such robust features and initiatives have put TECSYS’s WMS technology in a strong position to meet the needs of a new generation of visually driven computer users, who demand ease of use, have high expectations, and are intolerant to inefficiency,” said Frost & Sullivan Research Analyst Jithendranath Rabindranath. “In fact, the company’s visual logistics technology can now be seen as the new paradigm for attracting and retaining employees.
“To design and develop its novel WMS solution, TECSYS adopted the S-Coordinates Rutgers University Model (SCRUM) management process, which required the company to work closely with end users, ensuring that each sequential development was made using the knowledge gleaned from earlier development efforts. It also breaks down the WMS solution developmental process into smaller steps, significantly reducing the cost associated with restarting the process should there be a setback.”
The value additions resulting from this intensive developmental process have been instrumental in helping TECSYS’s WMS solution succeed. Another unique internal strategy that has worked for the company is the fostering of creativity among employees. Candidates with certain skills are placed in positions where their creativity is best utilized — a creative drive that other industry participants lack. Evidence of the company’s success can be found in the glowing feedback received from its healthcare customers and widespread acceptance among businesses dealing with high-cost products and experiencing shipping errors or delays.
“The immense flexibility of the company’s WMS technology will drive adoption rates among participants in the healthcare sector and enable penetration into diverse market sectors, including automotive and retail,” noted Jithendranath. “It is an ideal solution for businesses with high-volume distribution and traceability requirements for complex and customer-specific products.”
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About TECSYS
TECSYS is a leading supply chain management software provider that delivers powerful enterprise distribution, warehouse and transportation logistics software solutions. The company’s customers include over 600 mid-size and Fortune 1000 corporations in healthcare, heavy equipment, third-party logistics, and general wholesale high-volume distribution industries. TECSYS’ shares are listed on the Toronto Stock Exchange under the ticker symbol TCS.
Solutions and general info: info@tecsys.com
Investor relations: investor@tecsys.com
Media relations: media@tecsys.com
TECSYS Inc.
+1-514-866-0001 or +1-800-922-8649
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
Contact:
Mireya Espinoza
P: +1.210.247.3870
F: +1.210.348.1003
E: mireya.espinoza@frost.com
Synageva BioPharma™ Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency
LEXINGTON, Massachusetts, July 1, 2014 /PRNewswire/ — Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced today that the global, randomized, double-blind, placebo-controlled Phase 3 ARISE trial of sebelipase alfa in 66 children and adults with lysosomal acid lipase deficiency (LAL Deficiency) met the primary endpoint of normalization of alanine aminotransferase (ALT), a marker of liver injury (p=0.027). In addition, sebelipase alfa significantly improved multiple other disease-related abnormalities as measured by a number of secondary endpoints.
LAL Deficiency patients enrolled in the trial presented with multiple clinically important abnormalities at baseline. Fibrosis and/or cirrhosis was documented in 100% (32/32) of patients who had baseline biopsies even though the median age of patients enrolled in the trial was only 13 years. Dyslipidemia was common at baseline, with a median LDL cholesterol of 204 mg/dl (which is in the very high category of >190 mg/dl), and an abnormally low median HDL cholesterol of 32.5 mg/dl.
Impact on Dyslipidemia. In addition to demonstrating a statistically significant improvement in ALT normalization, sebelipase alfa improved dyslipidemia with statistically significant reductions in LDL cholesterol (p<0.001), non-HDL cholesterol (p<0.001) and triglycerides (p=0.038), as well as a statistically significant increase in HDL cholesterol (p<0.001), all compared with placebo from baseline to the completion of the double-blind treatment period of 20 weeks.
Impact on Other Liver Abnormalities. Statistically significant improvements were also seen in AST normalization (p<0.001) and in liver fat fraction as assessed by multi-echo gradient echo (MEGE) magnetic resonance imaging (MRI) (p<0.001). Paired liver biopsies at baseline and at 20 weeks were available in 26/66 patients. Of these, 63% of patients treated with sebelipase alfa (10/16) had improvement in hepatic steatosis compared to 40% of patients on placebo (4/10). This difference did not reach statistical significance. Although the hierarchical fixed-sequence testing statistical methodology did not allow for a formal assessment of the remaining secondary endpoint, decreased liver volume as assessed by MRI was observed with sebelipase alfa compared with placebo.
Sebelipase Alfa Safety Overview. The sebelipase alfa and placebo arms had a similar number of patients with reported adverse events. Most adverse events during the double-blind treatment period were mild in nature and unrelated to sebelipase alfa. The adverse events occurring in three or more sebelipase alfa treated patients, and which occurred more commonly in treated than placebo patients, were headache (28% versus 20%), pyrexia or body temperature increased (25% versus 23%), oropharyngeal pain (17% versus 3%), nasopharyngitis (11% versus 10%), abdominal pain (8% versus 3%), constipation (8% versus 3%), nausea (8% versus 7%) and asthenia (8% versus 3%). One patient discontinued from the double-blind portion of the clinical trial. This patient experienced a serious adverse event described as an atypical infusion related reaction following treatment with sebelipase alfa. Four patients in the placebo arm and two patients in the sebelipase alfa arm experienced infusion associated reactions during the double-blind portion of the study.
“This global Phase 3 study in children and adults with LAL Deficiency builds upon our earlier insights into both the manifestations of the disease and the impact of sebelipase alfa. The results from this controlled trial demonstrate the effects of sebelipase alfa on a broad range of disease-related abnormalities and are consistent with the ability of enzyme replacement therapy to address the root cause of the disease. We look forward to providing further details of the study at a future medical conference,” said Anthony Quinn, MBChB, PhD, FRCP, Executive Vice President and Chief Medical Officer at Synageva.
“The positive Phase 3 results with sebelipase alfa are an important step forward for patients and families affected by LAL Deficiency,” said Sanj K. Patel, President and Chief Executive Officer at Synageva. “We will continue to build towards a sustainable and generational company that is committed to helping patients with rare and devastating diseases.”
Clinical Trial Design. The ARISE (Acid Lipase Replacement Investigating Safety and Efficacy) trial enrolled 66 children and adults with LAL Deficiency. Patients enrolled in the trial were randomized on a one-to-one basis to every other week infusions of sebelipase alfa (1 mg/kg) or placebo for the double-blind treatment period of 20 weeks. Details of the Phase 3 ARISE trial will be submitted to a future medical conference and for publication.
Together with safety and efficacy data from the Phase 2/3 study in infants with rapidly progressive LAL Deficiency, in which six of the nine infants enrolled met the primary endpoint of survival to 12 months of age, data from this Phase 3 study in children and adults will be used to support global submissions for product registration. Synageva continues to plan to complete submission of a Biologic License Application (BLA) to the U.S. Food & Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sebelipase alfa for the treatment of LAL Deficiency by the end of the first quarter of 2015.
Conference call details
Synageva’s management team will host a conference call today at 4:30 p.m. EDT to review the top-line results. To participate in today’s call by telephone, please dial (877) 445-4603 for U.S. callers or (443) 295-9270 for International callers. In addition, the conference call will be webcast live from the “Webcasts & Presentations” section of the Investor Relations tab on the home page of Synageva’s website at www.synageva.com.
Sebelipase alfa for LAL Deficiency
LAL Deficiency is a rare autosomal recessive lysosomal storage disease caused by a marked decrease in LAL enzyme activity. LAL Deficiency presenting in children and adults, historically called Cholesteryl Ester Storage Disease (CESD), is an underappreciated cause of cirrhosis and accelerated atherosclerosis. These complications are due to the buildup of fatty material in the liver, blood vessel walls and other tissues as a result of the decreased LAL enzyme activity. Infants presenting with LAL Deficiency, historically called Wolman disease, show very rapid progression with death, usually in the first six months of life. Affected infants develop severe liver complications, malabsorption, and growth failure.
Sebelipase alfa is a recombinant form of the human LAL enzyme being developed by Synageva as an enzyme replacement therapy for LAL Deficiency. Synageva is evaluating sebelipase alfa in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa received fast track designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants.
Synageva routinely posts information that may be important to investors in the “Investor Relations” section of the company’s website at www.synageva.com. Synageva encourages investors and potential investors to consult this website regularly for important information about the company.
Further information regarding Synageva is available at www.synageva.com.
Forward-Looking Statements
This news release contains “forward-looking statements”. Such statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “intend,” “believe,” “may,” “will,” “estimate,” “forecast,” “project,” or words of similar meaning. These forward-looking statements address, among other matters, our plans to submit the Phase 3 ARISE results for future publication and our plans and timing to submit sebelipase alfa for regulatory approval. Many factors may cause actual results to differ materially from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties some of which are known, including, unanticipated delays in our submission timelines, risk that the outcomes of our clinical trials may not support registration or further development of our product candidates due to safety, efficacy or other reasons, the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory authorities, and the risks identified under the heading “Risk Factors” in Synageva’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 1, 2014 and other filings Synageva periodically makes with the SEC, and others of which are not known. Preclinical and clinical trial data are subject to differing interpretations, and regulatory agencies, as well as medical and scientific experts, may not share Synageva’s views regarding this data or its implications. Synageva may encounter problems or delays in the regulatory process. No forward-looking statement is a guarantee of future results or events, and investors should avoid placing undue reliance on such statements. Synageva undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
“Dedicated to Rare Diseases®” is a registered trademark of Synageva. “Synageva BioPharma™” is a trademark of Synageva BioPharma Corp.
Logo – http://photos.prnewswire.com/prnh/20140522/90728
New 3D Systems Printer Range, Now Available from RS Components in Greater China and South East Asia, Bring Faster Print Speeds and Higher Resolution to Consumers and Professionals
 |
Introduction of 3D Systems’ 3D printers, 3D scanners, and cartridges, sets RS among the foremost distributors of 3D printing products globally
SINGAPORE, June 19, 2014 /PRNewswire/ — RS Components (RS), the trading brand of Electrocomponents plc (LSE:ECM), the world’s leading high service distributor of electronics and maintenance products, has introduced an array of 3D printers and print technologies from 3D Systems, a leading provider of 3D printing centric design-to-manufacturing solutions including 3D printers, print materials and cloud sourced on-demand custom parts for professionals and consumers.
Cube 3 and CubePro 3D printers
The 3D Systems products now stocked by RS in China and South East Asia include a range of 3D printers, 3D scanners and cartridges, comprising: the second generation Cube® plug-and play 3D printer; the CubeX® desktop 3D printer; and the Sense™ 3D scanner. Also available to pre-order from RS, for delivery from July 2014, are the very latest third generation Cube® 3 and CubePro™ 3D printers.
Cube® 3 is the only dual material, plug-and-play, child-safe IEC 60950 certified 3D printer that is easy to use. The printer is supplied with two starter cartridges in neon green and white, and 25 designs to start printing quickly. Cube 3 delivers up to two times faster print speed and accuracy than other printers on the market for printed parts up to 6″ cubed. It prints in two materials and up to two colours, simultaneously using compostable PLA and recyclable ABS plastics. Both materials are available in 23 different colour cartridges. Instant material loading makes it easier than changing an ink cartridge. The new non-clog technology and moisture-lock cartridges ensure long shelf life and total material usage, improving print quality and sustainability.
The professionally capable CubePro™ is the only triple material, controlled print chamber engineer’s desktop 3D printer. It prints 2.5 times larger than any other desktop prosumer and hobbyist printer (10.8″ x 10.45″ x 9.5″ or 275 mm x 265 mm x 240 mm), and guarantees faster, more precise prints with easy feed cartridges for prolonged material life. In addition to ABS and PLA plastic, CubePro also supports a new engineering grade nylon material, perfect for end-use applications.
Cube 3 and CubePro both offer multi-colour and multi-materials, ultra-high resolution settings of 70-micron thin print layers to give smoothness and fine detail, faster print speeds, and printing on-the-go from a smartphone app to be released by 3D Systems when product shipments begin. Both printers feature a colour touchscreen with an intuitive user interface and LEDs highlighting prints in action, and are equipped with fast Wi-Fi and Bluetooth connectivity.
The second generation Cube® is a simple plug-and-play printer offering 3D printing capability with fast print speed and high accuracy for printed parts up to 5.5″ cubed. Cube prints in two materials, compostable PLA and recyclable ABS plastics, available in a variety of colours. It offers a choice of print mode fill density: light, medium and solid in both PLA and ABS plastics with optional easy, peel away supports for the most complex prints. Certified to IEC 60950 for safe-at-home use, Cube uses a smart cartridge system that detects material type automatically based on the cartridge, so no adjustment of the print settings is required. RS is stocking PLA cartridges for Cube in a range of nine colours.
CubeX® is a desktop 3D printer, offering the largest print volume in its category and mono, dual or triple-colour printing. CubeX provides professional printability with 1,070 cubic inches of space, or 10.8″ x 10.45″ x 9.5″. There are several options for print modes, including a choice of accuracy: High Definition (125 Micron), Crisp Definition (250 Micron) or Standard Definition (500 Micron), and a choice of print fill density: light, medium or solid. CubeX prints in both PLA and ABS plastics, and is available in multiple colour options: the basic CubeX single colour: CubeX Duo, offering dual colour and materials; and CubeX Trio, the top-of-the range triple colour, multi-material option. Like all 3D Systems printers, CubeX uses the smart MoistureLock cartridge system. Ten CubeX PLA cartridge colour options are available to purchase from RS.
Sense™ is the first 3D scanner designed for the consumer and optimized for 3D printing. Sense is handheld, and delivers precise instant physical photography, processing data in seconds for an instantly 3D printable file. It comes with an intuitive user interface with easy and automated zoom, track, focus, crop, enhance and share tools. Sense can scan objects ranging from 20mm³ to 3m³, making it possible to capture people, objects and places on the go.
About RS Components
RS Components and Allied Electronics are the trading brands of Electrocomponents plc, the global distributor for engineers. With operations in 32 countries, we offer around 500,000 products through the internet, catalogues and at trade counters to over one million customers, shipping more than 44,000 parcels a day. Our products, sourced from 2,500 leading suppliers, include semiconductors, interconnect, passives and electromechanical, automation and control, electrical, test and measurement, tools and consumables.
Electrocomponents is listed on the London Stock Exchange and in the last financial year ended 31 March 2014 had revenues of GBP1.27bn.
For more information, please visit the website at www.rs-online.com.
Further information is available via these links:
@RSElectronics; @alliedelec; @designsparkRS
RS Components on Linkedin
http://www.linkedin.com/company/rs-components
RS Components on Weibo
http://e.weibo.com/u/3206377000?type=0
Relevant Links:
Electrocomponents plc
www.electrocomponents.com
RS Components
www.rs-online.com/
DesignSpark
www.designspark.com
RS Components
Tan Soo Chun
Public Relations Manager – Asia Pacific
Email: soochun.tan@rs-components.com
Telephone: +65-6391-5745
Edelman Public Relations (Singapore)
Yvette Yeo
Manager
Email: yvette.yeo@edelman.com
Telephone: +65-6347-2355
Official Launch Of BornToBunk.com Accommodation Reservation Site For Affordable Stays In The Asia Pacific
SINGAPORE, July 2, 2014 /PRNewswire/ — BornToBunk.com is an online travel reservation portal, with specialty in properties within the Asia Pacific, for the budget, independent and youth travel (BIYT) market. Headquartered inSingapore, BornToBunk.com connects travelers to their choice accommodations in Asia, the world’s top travel destination.
To view the multimedia assets associated with this release, please click:http://www.multivu.com/players/English/7257651-born-to-bunk-launches-accommodation-reservation-site-asia-pacific-travel
The portal offers the convenience of planning multiple accommodations on travelers’ Asian trail within one seamless transaction. In addition, BornToBunk.com fosters a sense of camaraderie and community with the provision of a public blogging platform. This platform allows public contributors, from novices to seasoned travel bloggers, to share personal travel stories and anecdotes and in exchange, be rewarded with ‘Gold’ travel credits, which may be redeemed against online transactions on BornToBunk.com, with no minimum spend.
Asia – World’s Top Travel Destination
World Tourism Organization (UNWTO) reported that demand for international tourism was strongest for destinations in Asia and the Pacific in 2013, where the number of international tourists grew by 6% to reach 248 million. Long-term prospects continue to be the strongest for this region, where arrivals are forecast to increase by 4.9% yearly, to reach 535 million in 2030.
“We would like to see visitors and travelers to and within Asia Pacific, discovering multiple cities within a single leg of their journey. Its rich cultural fabric makes it an excellent destination for exploration, and somewhere just an hour away is a whole new world begging to be explored,” said founder and avid backpacker, Magdalene Wan. “It only takes an hour from Angkor (Siem Reap), one of the most important archaeological sites of Southeast Asia, to Ho Chi Minh’s (Vietnam) Cu Chi tunnels, location of several military campaigns during the Vietnam War.”
To celebrate the launch of the site, BornToBunk.com has also kickstarted a social media contest, “Travel Treasures”, inviting the public to share their fondest travel memories for a chance to win travel prizes including a Pentax DSLR K-50, Ricoh CX6 cameras, free accommodation in Asia, and other attractive prizes. Contest ends26 August 2014. See more at www.borntobunk.com/traveltreasures.
Twitter-friendly headline:
BornToBunk.com official launch | #Giveaway Alert -Win Prizes
Find out more socially by searching for #BornToBunk & #TravelTreasures
Tags: @borntobunk, #borntobunk, #asiantrail
CONTACT: Cass Kong, cass@borntobunk.com, +65-9644-9971, Visit www.borntobunk.com to learn more.
Heraeus to Exhibit at Intersolar North America 2014 Exhibition and Conference
WEST CONSHOHOCKEN, Pa., July 1, 2014 /PRNewswire/ — The Heraeus Photovoltaics Business Unit will be attending Intersolar North America 2014 at the Moscone Center in San Francisco, California from July 8th through 10th, showcasing their new products for standard to ultra LDE cells and PERC cell designs during the exhibition.
“Heraeus Photovoltaics is pleased to be exhibiting at Intersolar NA for another year. The first metallization pastes for c-Si solar cells developed by Heraeus were created in North America and this region continues to be critical to our success”, states Andreas Liebheit, Global Manager of the Heraeus Photovoltaics Business Unit. “At this year’s show, we are proud to exhibit our SOL325 Series of pastes for PERC cell designs. This paste, along with our front-side metallization pastes, was used by the Institute for Solar Energy Research Hamelin (ISFH) to produce PERC cells with a record efficiency of 21.2%. We will also showcase our newest front-side metallization pastes for standard to ultra lightly doped emitter cells: the SOL9620 and SOL9621 Series. Our SOL9620 Series has shown excellent results on monocrystalline cells, with absolute efficiency gains up to 0.25%. Our SOL9621 Series has demonstrated greater than 0.10% absolute efficiency gains on crystalline silicon cells and possesses a flexible processing window, providing customers with very consistent cell efficiencies during production runs.”
Heraeus will also be exhibiting their SOL9650 Series for n-type cell designs. To learn more about Heraeus’ products and services for the photovoltaic industry, visit us at this year’s Intersolar North America at the Moscone Center West Hall on level 1 in booth 7611. You can also go to www.pvsilverpaste.com for more information.
About the Heraeus Photovoltaics Business Unit
The Heraeus Photovoltaics Business Unit is an industry leading developer and manufacturer of silver metallization pastes for the photovoltaic industry. For over 40 years, Heraeus has built a reputation of innovation, extensive research and new product development in thick film technologies for some of the most prominent companies within a variety of industries. In the field of photovoltaics, the Heraeus Photovoltaics Business Unit applies this history and its innovative technology to offer metallization pastes for solar cell applications. The Heraeus SOL Series of silver pastes is specially formulated to provide higher efficiencies and wider processing windows, resulting in better yields and higher output for cell manufacturers.
The Hanau based precious metals and technology group Heraeus is a globally active family run enterprise with a history of more than 160 years. We provide high end solutions to our customers to strengthen their long-term competitive position. Our areas of competence include precious metals, materials and technologies, sensors, biomaterials and medical devices, quartz glass and specialty light sources. In the financial year 2013, Heraeus achieved revenues from the sales of products of EUR 3.6 billion, while the revenues from precious metal trading were EUR 13.5 billion. With about 12,500 employees in more than 110 companies world-wide, Heraeus holds leading positions in the global markets it participates.
Logo – http://photos.prnewswire.com/prnh/20140211/PH60816LOGO
Diva Coffee: 100% Carbon Offset ECO Coffee
SYDNEY, July 2, 2014 /PRNewswire/ — When Jim Storey started Diva Coffee, he believed that through business he could make the world a better place.
“When you run your own business you get to make your own choices,” said Jim, owner of Diva Coffee. “So I decided to make positive choices for our planet and the communities supported by the coffee industry.”
And so Diva ECO Coffee was born – coffee that’s Ethical, Community focused and Organic. It’s also 100% carbon offset.
“We’ve chosen the best of the best in terms of Ethical products,” Jim said. “The coffee is Fair Trade certified which ensures that farmers get paid a reasonable amount for their work. By choosing Organic we’re ensuring the sustainability of the coffee farms and communities that the beans are from, and 100% carbon offsets are helping keep the planet safe for our children.”
A study in 2012 published in the Journal of Agricultural Science and Technology regarding the carbon footprint of coffee found that for every kilo of coffee harvested, approximately 5kg of carbon was released in its journey across the supply chain. So from the tree to your waste bin 5kg of carbon is released as the coffee is harvested, transported, roasted, packaged, ground and consumed. The packaging in capsules is even higher with a greater carbon footprint.
“The most exciting part of launching this product is choosing where to buy the carbon credits,” said Jim. “It’s like Christmas having money to spend helping others, especially choosing projects like the Kenya Lifestraw Project.”
Traditionally water is purified in Kenya by boiling it – and the fuel for heating the water is the local forest. The Kenya Lifestraw Carbon Offset Program reduces deforestation by providing a healthy alternative using clean drinking water filters. Not only is this reducing carbon, providing clean drinking water is also saving lives.
“As soon as I saw the Kenya LifeStraw program I fell in love with it,” said Jim. “As a parent I can only imagine the anguish of having to give your children potentially harmful drinking water. The LifeStraw project ticked all the environmental and ethical boxes for me.”
To read more about this project, or Diva Coffee, head over to divacoffee.com.au.
Contact:
Jim Storey, CEO
15/20 Narabang Way
Belrose NSW 2085
Phone: +612-9986-3053
Email: sales@divacoffee.com.au
About Diva Coffee
Diva Coffee have believed in Excellence with Attitude for over 8 years. They are an Australian franchise chain based on the Northern Beaches in Sydney, Australia. Diva Coffee are the exclusive importers and distributors of Italian HLF coffee machines. They are also multi-award winning coffee roasters. To view the promo photo, please visit http://divacoffee.com.au/wp-content/uploads/2014/02/kenya-lifestraw.jpg.
Diva Coffee
15/20 Narabang Way,
Belrose, NSW, 2085
Phone: +612-9986-3053
Fax: +61-2-8588-1235
www.divacoffee.com.au
British Brand Challenges Swiss Luxury Watch Industry
LONDON /PRNewswire/ — British luxury watch brand Christopher Ward (London) has stunned the global $23 billion Swiss watch industry by announcing the creation of its own in-house movement – the engine of the watch – Calibre SH21.
To view the Multimedia News Release, please click:
http://www.multivu.com/mnr/71400574-christopher-ward-calibre-SH21-london
Chris Ward, eponymous co-founder of the brand, describes this as “probably the most significant watch industry development by a British brand in the past 50 years”.
Established in 2004, Christopher Ward pioneered a radical new business model as the world’s first pure online luxury watch brand. Around 40% sales are overseas, the US being the single largest market, selling more mechanical watches than any other UK-based brand. Now, despite being a young and independent brand, the company has advanced to a new level with the launch of its own in-house movement – Calibre SH21.
Mike France, one of the three co-founders of Christopher Ward, explains the significance of the launch: “Last year, the CEO of a major Swiss luxury watch brand heard rumours about SH21 and his – frankly, affronted – comment was “What gives you the license to do that?”
“We give ourselves license to do this. Ten years ago we launched the world’s first pure online business model for luxury watches; a new paradigm in blending supreme quality with unprecedented value that challenged the industry norm. Today, we are advancing to a new level of independence that strengthens the future growth of the business and enables us to develop a family of movements, the first of which is the beautiful C9 Harrison 5 Day Automatic, housing the Calibre SH21, which we also launched today.”
“Our merger with Synergies Horlogeres embeds the experienced industry know-how of Jorg Bader and the extraordinary horological design skills of young watchmaker Johannes Jahnke into our new merged business – Christopher Ward London Holdings. Together, we will deliver further surprises to the luxury watch industry and take our brand to a new level.”
Production of the new movement has been facilitated through the merger. Many brands in the luxury watch industry face intense pressure from the severely restricted supply line strategy adopted by the industry’s largest manufacturer of movements, Swatch Group. Calibre SH21 provides Christopher Ward with a greater degree of independence and security to set its own path.
View full release here
www.kavanaghcommunications.com/press-releases/british-brand-challenges-swiss-luxury-watch/
2014 CGAP Photo Contest Now Open for Entries
WASHINGTON, July 1, 2014 /PRNewswire/ — The annual CGAP Photo Contest, which aims to highlight stand-out photography from amateurs and professionals around the world depicting financial inclusion, is now open for entries.
To view the multimedia assets associated with this release, please visit:http://www.multivu.com/players/English/7065952-cgap-2014-photo-contest-financial-inclusion
Photo – http://photos.prnewswire.com/prnh/20140701/123582
Logo – http://photos.prnewswire.com/prnh/20110412/MM81963LOGO
Submit your entries to the 2014 CGAP Photo Contest online at CGAP.org before October 8, 2014.
CGAP is looking for photos that illustrate the remarkable ways access to a variety of financial services, such as savings, insurance, payments, and credit, can help poor people manage their complex financial situations. Mobile financial services are one tool millions of poor people use to enhance their lives, but they are not the only option. Community-based savings groups, small enterprises, and microfinance are other examples of financial inclusion in action. Submissions to the CGAP Photo Contest may represent a range of products, institutions, and approaches, and may touch on a broad variety of social, economic, developmental, and technological issues. Entries are welcomed from all regions, in both rural and urban settings.
Past winners have included stunning and creative images that have been shared with organizations working in financial inclusion and global media. The 2013 contest was the most competitive to date, with 3,890 entries from over 90 countries. Last year’s winning photos received excellent exposure globally and were featured in the online galleries by BBC Mundo, BBC Vietnam, Huffington Post, and Business Insider to name a few.
Many prizes will be issued in 2014, including a first, second, and third prize, as well as a People’s Choice winner determined by popular vote.
Help us show the world, through photography, how financial inclusion can improve the lives of the poor by submitting your photos and sharing this announcement with your networks. Submit your photos today andshare the contest announcement with your networks.
About CGAP
CGAP (the Consultative Group to Assist the Poor) is a global partnership of 34 leading organizations that seek to advance financial inclusion. CGAP develops innovative solutions through practical research and active engagement with financial service providers, policy makers, and funders to enable approaches at scale. Housed at the World Bank, CGAP combines a pragmatic approach to responsible market development with an evidence-based advocacy platform to increase access to the financial services the poor need to improve their lives. More atwww.cgap.org.
Asia Fresh News 